We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing ALX148 as a foundational checkpoint immunotherapy

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, ALX148, will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.

Latest News updated at 13:42:35 UTC

Jul 03, 2021

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

Jun 14, 2021

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies

Jun 10, 2021

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer

Twitter

ALX Oncology has announced new data from ASPEN-01, the Phase 1b Study of ALX148, showing robust objective response in patients with #gastric or #gastroesophageal junction cancer at the @myESMO #WorldGI2021: https://bit.ly/2TyehKk

ALX Oncology today announced updates on its ALX148 Phase 2 studies in patients with advanced head and neck #squamouscellcarcinoma: https://bit.ly/3iG1Oy0

ALX Oncology announced a clinical trial collaboration and #supplyagreement with @LillyPad to evaluate the combination of ALX148 & CYRAMZA® (ramucirumab) for the treatment of patients with HER2-positive #gastriccancer or #gastroesophagealjunctioncancer: https://bit.ly/3whpwF6

Load More...

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, ALX148, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.

LEARN MORE